Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)

Nishi,Tomohiro; Hamamoto,Yasuo; Nagase,Michitaka; Denda,Tadamichi; Yamaguchi,Kensei; Amagai,Kenji; Miyata,Yoshinori; Yamanaka,Yasuhiro; Yanai,Kai; Ishikawa,Tsutomu; Kuroki,Yoshifumi; Fujii,Hirofumi

doi:10.3892/ol.2016.4532

Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)

Authors:
- Tomohiro Nishi
- Yasuo Hamamoto
- Michitaka Nagase
- Tadamichi Denda
- Kensei Yamaguchi
- Kenji Amagai
- Yoshinori Miyata
- Yasuhiro Yamanaka
- Kai Yanai
- Tsutomu Ishikawa
- Yoshifumi Kuroki
- Hirofumi Fujii
View Affiliations

Affiliations: Kawasaki Municipal Ida Hospital, Kawasaki Comprehensive Care Center, Kawasaki, Kanagawa 211‑0012, Japan, Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi 320‑0834, Japan, Department of Clinical Oncology, Jichi Medical University Hospital, Shimotsuke, Tochigi 329‑0498, Japan, Division of Gastroenterology, Chiba Cancer Center, Chiba 260‑8717, Japan, Division of Gastroenterology, Saitama Cancer Center, Saitama 362‑0806, Japan, Department of Gastroenterology, Ibaraki Central Hospital, Kasama, Ibaraki 309‑1793, Japan, Department of Medical Oncology, Saku Central Hospital, Saku, Nagano 384‑0301, Japan, Department of Diagnostic Radiology, Dokkyo Medical University, Tochigi 321‑0293, Japan, Department of Diagnostic Imaging, Fukuoka University, Fukuoka 815‑0032, Japan
Published online on: May 6, 2016 https://doi.org/10.3892/ol.2016.4532
Pages: 4049-4054

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Little is known about the clinical impact of salvage panitumumab with irinotecan for metastatic colorectal cancer (mCRC) patients. The present study conducted a single‑arm, multicenter phase II trial for mCRC with skin toxicity prevention program. The subjects were mCRC patients with wild‑type KRAS, who showed resistance to fluoropyrimidine, oxaliplatin and irinotecan. Panitumumab was administered at a dose of 6 mg/kg every 2 weeks by intravenous infusion over 60 min, and irinotecan was administered at a dose of 100‑180 mg/m2 every 2 weeks by intravenous infusion over 90 min, depending on the preceding treatment dose. To prevent skin toxicities, a moisturizer was applied and oral antibiotics (100 mg minocycline twice daily) were initiated for 6 weeks. The primary endpoint was the response rate (RR) determined by independent reviewers. Secondary endpoints were the disease control rate (DCR), progression‑free survival (PFS) time, overall survival (OS) time and adverse events. A total of 35 patients were enrolled between October 2010 and March 2012. The median age was 61 years (range, 41‑76 years), with 25 male and 10 female patients. The initial irinotecan dose was 150 mg/m2 in 19 patients and 180 mg/m2 in 1 patient. The remaining patients were treated with ≤120 mg/m2. A central review indicated a partial response in 8 patients (22.9%) and stable disease in 6 patients (17.1%), with an RR of 22.9% (95% confidence interval, 12.1‑39.0) and a DCR of 40%. The RR of the patients with standard‑dose irinotecan (150 or 180 mg/m2) was 30%, although that of low‑dose irinotecan (100‑120 mg/m2) was 13%. The median PFS time was 2.7 months, and the median OS time was 6.3 months. A grade 3 or above acne‑like rash developed in 25.7% of patients. In conclusion, panitumumab and irinotecan as salvage therapy for mCRC KRAS wild‑type patients with skin toxicity prevention exhibits limited efficacy. In particular, the effect of low‑dose irinotecan with panitumumab appears to be clinically insignificant. Routine use of skin toxicity prevention is currently under evaluation.

View Figures

View References

1	Winder T and Lenz HJ: Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology. 138:2163–2176. 2010. View Article : Google Scholar : PubMed/NCBI
2	Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009. View Article : Google Scholar : PubMed/NCBI
3	Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
4	Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
5	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
6	Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III: Eastern Cooperative Oncology Group Study E3200: Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the eastern cooperative oncology group study E3200. J Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar : PubMed/NCBI
7	Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
8	Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, et al: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 32:abstract LBA3. 2014.
9	Van Cutsem E, Cervantes A, Nordlinger B and Arnold D: ESMO, Guidelines Working Group: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (25 Suppl 3): iii1–iii9. 2014. View Article : Google Scholar : PubMed/NCBI
10	Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
11	Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 30:3499–3506. 2012. View Article : Google Scholar : PubMed/NCBI
12	Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, et al: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol. 15:601–611. 2014. View Article : Google Scholar : PubMed/NCBI
13	Madi A, Fisher D, Wilson RH, Adams RA, Meade AM, Kenny SL, Nichols LL, Seymour MT, Wasan H, Kaplan R, et al: Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial. Br J Cancer. 107:1037–1043. 2012. View Article : Google Scholar : PubMed/NCBI
14	Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
15	Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F and Yassine M: Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 28:1351–1357. 2010. View Article : Google Scholar : PubMed/NCBI
16	James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Mudal A and Therasse P: Measuring response in solid tumors: Unidimensional versus bidimensional measurement. J Natl Cancer Inst. 91:523–528. 1991. View Article : Google Scholar
17	Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006.http://www.jcog.jp/doctor/tool/CTCAEv3J_070308.pdfAccessed. March 08–2007
18	Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 25:1658–1664. 2007. View Article : Google Scholar : PubMed/NCBI
19	Doi T, Ohtsu A, Tahara M, Tamura T, Shirao K, Yamada Y, Otani S, Yang BB, Ohkura M and Ohtsu T: Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. Int J Clin Oncol. 14:307–314. 2009. View Article : Google Scholar : PubMed/NCBI
20	André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, et al: Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: A GERCOR efficacy, tolerance and translational molecular study. Ann Oncol. 24:412–419. 2013. View Article : Google Scholar : PubMed/NCBI
21	Hasegawa H, Yoshida M, Taira K, Sugimoto N, Kii T, Takeda K, Yoshinami T, Sakai D, Satou T, et al: A Phase II study of pmab + IRI FOR mCRC PTS with WildKRAS, resistant to fluoropyrimidine, oxaliplatin and IRI (OGSG1001). Ann Oncol. 25(Suppl 5): v44–v74. 2014.
22	Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 28:4706–4713. 2010. View Article : Google Scholar : PubMed/NCBI
23	Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, et al: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. Lancet Oncol. 14:749–759. 2013. View Article : Google Scholar : PubMed/NCBI
24	Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, et al: EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
25	Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, et al: Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol. 11:617–627. 2015. View Article : Google Scholar : PubMed/NCBI
26	Schimanski CC, Moehler M, Zimmermann T, Wörns MA, Steinbach A, Baum M and Galle PR: Cetuximab-induced skin exanthema: Improvement by a reactive skin therapy. Mol Med Rep. 3:789–793. 2010.PubMed/NCBI